Cargando…

Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study

BACKGROUND: There is no consensus on the effect of sorafenib dosing on efficacy and toxicity in elderly patients with hepatocellular carcinoma (HCC). Older patients are often empirically started on low-dose therapy with the aim to avoid toxicities while maximising clinical efficacy. We aimed to veri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hajiev, Saur, Allara, Elias, Motedayеn Aval, Leila, Arizumi, Tadaaki, Bettinger, Dominik, Pirisi, Mario, Rimassa, Lorenza, Pressiani, Tiziana, Personeni, Nicola, Giordano, Laura, Kudo, Masatoshi, Thimme, Robert, Park, Joong-Won, Taddei, Tamar H., Kaplan, David E., Ramaswami, Ramya, Pinato, David J., Sharma, Rohini
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852559/ https://www.ncbi.nlm.nih.gov/pubmed/33071284 http://dx.doi.org/10.1038/s41416-020-01116-9

Ejemplares similares

Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2021)

Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis
por: Ramaswami, Ramya, et al.
Publicado: (2016)

Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib
por: Howell, Jessica A., et al.
Publicado: (2017)

Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study
por: Howell, Jessica, et al.
Publicado: (2022)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2020)

Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study
por: Pinato, David J., et al.
Publicado: (2016)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
por: Personeni, Nicola, et al.
Publicado: (2018)

Targeted agents for second-line treatment of advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2019)

Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options
por: Personeni, Nicola, et al.
Publicado: (2020)

Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights
por: Cammarota, Antonella, et al.
Publicado: (2022)

Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment
por: Personeni, Nicola, et al.
Publicado: (2022)

Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma
por: Sakurai, Toshiharu, et al.
Publicado: (2017)

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
por: Arizumi, Tadaaki, et al.
Publicado: (2014)

ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma
por: Demirtas, Coskun O., et al.
Publicado: (2021)

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
por: Sharma, Rohini, et al.
Publicado: (2022)

Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
por: Jun, Tomi, et al.
Publicado: (2021)

Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner
por: Campani, Claudia, et al.
Publicado: (2020)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
por: Zanuso, Valentina, et al.
Publicado: (2023)

Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
por: Motedayen Aval, Leila, et al.
Publicado: (2020)

PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects
por: D’Alessio, Antonio, et al.
Publicado: (2021)

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
por: Fessas, Petros, et al.
Publicado: (2020)

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
por: Pinato, David J., et al.
Publicado: (2020)

The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges
por: D’Alessio, Antonio, et al.
Publicado: (2021)

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
por: D’Alessio, Antonio, et al.
Publicado: (2022)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
por: Wu, Yue Linda, et al.
Publicado: (2022)

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
por: Pinato, David J, et al.
Publicado: (2020)

Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?
por: Cammarota, Antonella, et al.
Publicado: (2023)

Cold-inducible RNA-binding protein promotes the development of liver cancer
por: Sakurai, Toshiharu, et al.
Publicado: (2015)

KRAS mutation in lung metastases from colorectal cancer: prognostic implications
por: Ghidini, Michele, et al.
Publicado: (2015)

Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study
por: Personeni, Nicola, et al.
Publicado: (2022)

Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients
por: Milana, Flavio, et al.
Publicado: (2022)

Sorafenib-Induced Acute Generalized Exanthematous Pustulosis
por: Cortese, Andrea, et al.
Publicado: (2023)

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
por: Muhammed, Ambreen, et al.
Publicado: (2021)

Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives
por: Personeni, Nicola, et al.
Publicado: (2021)

Immune-based therapies for hepatocellular carcinoma
por: Pinato, David J., et al.
Publicado: (2020)

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
por: Pinato, David J., et al.
Publicado: (2019)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Personeni, Nicola, et al.
Publicado: (2021)

Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review
por: Vogel, Arndt, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bi9ib8hs88mcoi0nuejuk8mq0r